MacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases.
Industries BiotechnologyHealth CareManufacturingHeadquarters Regions Washington DC Metro Area, East Coast, Southern US Founded Date 2000 Founders Alan Aderem, Jeffrey V. Ravetch, Ruedi Aebersold, Scott Koenig Operating Status Active Last Funding Type Post-IPO Equity Legal Name MacroGenics, Inc.
Stock Symbol NASDAQ:MGNX Company Type For Profit
Contact Email info@macrogenics.com Phone Number +1-3012515321
MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases.
The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's
Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology.
The company was founded in 2000 and is headquartered in Rockville, Maryland.